Stock Price & Analysis

Based on the provided data and current market conditions, ARGX stock appears to be in a challenging position. Here's the analysis:

Technical Analysis

The stock closed at $648.94 on January 24, 2025, with a -0.50% decline during regular trading hours and a slight -0.02% drop in post-market trading. The stock is currently trading near key Fibonacci levels, with resistance at $672.41 and support at $640.04.

Fundamental Factors

• RSI (14) at 55.68 indicates neutral momentum, neither overbought nor oversold
• MACD at 9.03 suggests some positive momentum but requires monitoring

Analyst Sentiment Recent analyst actions have been predominantly bullish:

• JMP Securities maintains Buy rating with $696 price target
• Truist Securities reiterates Strong Buy with $660 target
• HC Wainwright maintains Strong Buy with $717 target
• Multiple analysts have raised their price targets, indicating growing confidence

Key Developments

• Strong Q4 2024 preliminary revenue of $737M, beating consensus of $627.99M
• Company provided FY2024 revenue guidance of $2.2B, above consensus of $2.01B
• Received Japanese approval for VYVDURA in CIDP treatment, expanding global market presence

Recommendation Given the current price level and market conditions, selling ARGX at this point is not recommended. The stock shows:

1. Strong fundamental growth with better-than-expected revenue
2. Positive analyst sentiment with multiple price target increases
3. Technical indicators suggesting neutral to slightly positive momentum

Instead of selling, holding the position or even considering adding on pullbacks to support levels around $640 would be more advisable.

Based on the provided data and analyst reports, here's a price prediction analysis for ARGX stock in 2025:

ARGX is expected to reach $701-702 by end of 2025, representing a potential 3-4% upside from current price of $681.38, driven by strong commercial execution of VYVGART and expanding indications. The consensus among analysts remains strongly bullish, with multiple firms including JMP Securities ($696), Goldman Sachs ($813), and BofA ($761) maintaining Buy ratings.

The key factors supporting this price target:

1. Strong revenue growth with Q4 2024 preliminary revenue of $737M, significantly beating consensus of $627.99M

2. Management's guidance for FY2024 revenue of $2.2B, ahead of consensus $2.01B, demonstrating confidence in commercial momentum

3. Expanding therapeutic indications and global market presence, with VYVGART now available to 80% of gMG population in EU and successful launch in Japan

The technical indicators show RSI at 55.68 and positive MACD of 9.03, suggesting moderate upward momentum while avoiding overbought territory. The stock is trading above its 20-day moving average of $642.71, indicating near-term bullish trend.

The S1 support level for ARGX Stock is $640.04 ,The R1 resistant level for ARGX Stock is $672.41.

As of the end of day on 2025-01-24, the price of ARGX Stock was $681.38.

The target price for ARGX Stock according to analyst rating is 687.08, with the highest price target at 772.00 and the lowest at 600.00. Analysts have a Strong Buy rating on ARGX Stock overall.

The market cap of ARGX is $38.8B.

Based on the provided data, I'll analyze whether ARGX is overvalued through multiple aspects.

Valuation Analysis The current P/S ratio of 17.77x and P/B ratio of 6.03x indicate relatively high valuation multiples compared to the broader biotech sector. However, these metrics should be viewed in context of the company's exceptional growth trajectory.

Growth & Financial Performance ARGX has demonstrated remarkable revenue growth, with Q3 2024 product net sales reaching $573 million, representing 74% year-over-year growth and 20% sequential growth. The company achieved profitability with $14 million operating profit and maintains a strong cash position of $3.4 billion.

Market Position & Pipeline Value VYVGART's success in gMG and strong VYVGART Hytrulo launch in CIDP has exceeded expectations, treating over 300 patients by Q3's end. The company has established presence in major markets with VYVGART available to 80% of the gMG population in EU.

Analyst Consensus Recent analyst actions strongly support ARGX's valuation. Multiple analysts have raised price targets, with an average target of $701.18, suggesting modest upside potential from current levels. The consensus remains strongly bullish based on the company's commercial execution and pipeline potential.

Conclusion While traditional valuation metrics suggest ARGX appears expensive, the company's strong execution, market leadership in key indications, and robust growth trajectory justify the premium valuation. The stock is fairly valued at current levels considering its growth prospects and market position.

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Based on the provided data and analyst projections, here is the 2030 price prediction for ARGX stock:

ARGX stock is projected to reach $1,250-1,350 by 2030, driven by its strong pipeline in immunology and inflammation treatments and expanding global market presence. The company's robust revenue growth of 96% and strategic Vision 2030 goal of reaching 50,000 patients with 10 labeled indications supports this bullish outlook. Multiple analyst firms maintain "Strong Buy" ratings with near-term price targets around $700-770, indicating steady growth trajectory toward the 2030 target [1,3].

ARGX has a total of 1148 employees.